

The eCOA market is about to triple. Here's what that means for sponsors.

A new Research and Markets forecast puts global eCOA solutions on a ten-year path from **\$1.94B** to **\$7.46B**. The window for competitive advantage is still open — but not for long.

MARKET TODAY	FORECAST	CAGR
\$1.94B	\$7.46B	14.4%
2026	2036	Compound annual growth · 10-year

— WHY OBVIOHEALTH IS DIFFERENT

Most eCOA vendors built software first. We did it the other way around.

We ran decentralized trials for seven years before licensing ObvioGo as a platform. Every capability exists because we needed it to run a real study — not because a product team put it on a roadmap.

7^{yrs}

Operational history before launch

60+

Decentralized studies delivered

40

Countries of trial experience

— 4-6 VENDORS · 1 PLATFORM

What sponsors typically buy from 4-6 vendors, ObvioGo delivers as one.

Not by acquiring and stitching together point solutions — but because we built it as one no-code environment from the start. API-first integration with Oracle Clinical One, Medidata, and Veeva keeps your existing EDC stack in place.

- **ePRO**

Patient-reported outcomes, anywhere.

- **eConsent**

Compliant remote consent flows.

- **Participant Engagement**

Reminders, chat, adherence nudges.

- **Safety Monitoring**

Real-time alerts and visibility.

- **Device Integration**

Wearables and connected devices.

- **EDC Integration**

Oracle, Medidata, Veeva — API-first.

THE RESULT, IN PRACTICE

TIME TO DEPLOY

4 wks

vs. 12-16+ weeks on legacy platforms

EPRO COMPLIANCE

91%

portfolio-wide average

PARTICIPANT RETENTION

89%

across active studies

VENDOR CONSOLIDATION

4-6 → 1

point solutions replaced by one platform

Built to run trials. Not just support them.

LET'S TALK

See how ObvioHealth approaches eCOA for your therapeutic area. Source:

Research and Markets, Global eCOA Solutions Forecast, 2026.

obviohealth.com

Request a demo →